AR and prostate carcinoma: Taken together, these data demonstrate that NXP800 abrogates AR signaling, including AR-V7 transactivation, with associated growth reduction in ARSI-resistant prostate cancer cell lines and patient-derived prostate cancer models, suggesting that it may provide an attractive strategy to overcome persistent AR signaling and treatment resistance in lethal prostate cancer.